NMRANeumora Therapeutics, Inc.
Health Care
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations revised up 0.9% for Q1 2024
This is the 9th largest revision in NMRA's history.
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations
Q1 2024
As reported
$142.1MRestated
$143.4M0.9%
Verify against SEC filingsShow
As reported$142.1M
Accepted 2025-05-120000950170-25-069311
Restated$143.4M
Accepted 2026-05-070001193125-26-211825
CashAndEquivalents · reported 3 times · point-in-time, survivorship-free. Every figure traces to its filing above.
Track this the moment it happens
Get an alert the next time NMRA — or any company on your watchlist — restates a number. Every alert lands with the diff and its source filing.